Market analysis archive

		From the analyst's couch: Influenza vaccines The introduction of cell culture flu vaccines is set to revolutionize the market. 6 March 2006
		Fresh from the pipeline: Orencia The first selective costimulation modulator to be approved for arthritis 6 March 2006
		From the analyst's couch: The IBS market The IBS market is large and under-penetrated and is therefore attractive for novel, safe and efficacious therapies. 10 February 2006
		Galsulfase The first treatment approved mucopolysaccharidosis type VI. 10 February 2006
		From the analyst's couch: Insomnia market New therapies are leading to an expansion of the insomnia market. 9 January 2006
		Fresh from the pipeline: Arranon A new player in the treatment of T-cell malignancies. 9 January 2006
		From the analyst's couch: Authorized generics What factors influence whether launching a generic version of a branded product is within company strategies? 9 December 2005
		Fresh from the pipeline: Aptivus The first in a new class of non-peptidic HIV-1 protease inhibitors. 9 December 2005
		From the analyst's couch: Drug discovery alliances Early-stage deals continue to rise, especially in oncology. 7 October 2005
		Fresh from the pipeline: Tygacil The first in a new generation of tetracycline antibiotics. 7 October 2005
		From the analyst's couch: Wet age-related macular degeneration The market for therapeutics for the leading cause of blindness in the elderly remains largely untapped. 9 September 2005
		Fresh from the pipeline: Byetta The first in a new class of drugs that mimic the activity of blood-sugar-controlling peptides known as incretins. 9 September 2005
		From the analyst's couch: Therapeutic cancer vaccines The dearth of cancer vaccines is soon about to change. 5 August 2005
		Fresh from the pipeline: Azilect The first in a new generation of selective monoamine oxidase inhibitors. 5 August 2005
		From the analyst's couch: Valuation with cash multiples Although investors are changing their view of the 'optimal' risk-return profile, there seems to be plenty of willing buyers today for today's biotechs. 8 July 2005
		Fresh from the pipeline: Entecavir The most potent inhibitor of the hepatitis B virus DNA polymerase to be approved so far. 8 July 2005
		From the analyst's couch: Future of COX2 inhibitors How the selective COX2 inhibitor market is reacting to recent setbacks. 03 June 2005
		Fresh from the pipeline: Lyrica Pfizer's drug for neuropathic pain has been recently approved in the US. 03 June 2005
		From the analyst's couch: BioPharma licensing and M&A trends Well-managed or wisely-positioned licensing or acquisition deals that increase the biotechnological diversity of R&D represent strategic paths by which pharma companies can boost productivity. 1st April 2005
		Fresh from the pipeline: Azacitidine A pioneering example of an epigenetic-based drug exploited by cancer cells to inhibit the expression of genes that counteract malignant conditions. 1st April 2005
		From the analyst's couch: Raising HDL cholesterol Regulatory approval is unlikely to be based solely on surrogate-marker data, and demonstration of long-term safety will be absolutely crucial. 4th March 2005
		Fresh from the Pipeline: Macugen As well as being the first anti-angiogenic agent approved for a common eye disorder, Macugen is also the first approved therapeutic based on an RNA structure known as an aptamer. 4th March 2005
		From the analyst's couch: Rheumatoid arthritis market Rheumatoid arthritis treatment is dominated in volume by older, generic drugs, but the market for new biologics is growing rapidly. 7th January 2005
		Fresh from the Pipeline: Tarceva The first drug to increase survival in Phase III trials in patients with advanced non-small-cell lung cancer. 7th January 2005
		From the analyst's couch: Targeting protein kinases As already evidenced by sales of Glivec, protein kinase-targeted drugs can achieve blockbuster status. 3rd December 2004
		Fresh from the pipeline: Avastin The first approved agent to target tumour angiogenesis looks set to become a blockbuster. 3rd December 2004
		From the analyst's couch: Killing the messenger The constantly improving techniques for genetic manipulation make it ever more enticing to consider targeting mRNA as a therapeutic strategy. 5 October 2004
		Fresh from the pipeline: Alimta An anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be approved by the FDA for the treatment of the rare cancer malignant pleural mesothelioma. 5 October 2004
		From the Analyst's couch: Cardiovascular combinations Drug companies have taken the next, dramatic step of developing and creating combination products outside of hypertension and for other cardiovascular disease states. 3 September 2004
		Fresh from the pipeline: Ketek After a delay in approval owing to safety issues, will this first-in-class antibacterial drug now attain its predicted blockbuster status? 3 September 2004
		From the analyst's couch: The animal health market The veterinary medicines industry has an important role in maintaining the health of food and companion animals. 29 November 2002
		From the analyst's couch: The evolution of biotech Twenty years ago, the launch of recombinant insulin signalled the birth of biotech. How has the biotech industry developed and how is it adapting to the current market? 1 November 2002
		From the analyst's couch: Drug life-cycle technologies Protecting the life cycle of patented drugs is becoming more important than ever for companies. 3 October 2002
		From the analyst's couch: Erectile-dysfunction therapies What are the phosphodiesterase 5 (PDE5) inhibitors and other therapies that are likely to compete with Viagra? 30 August 2002
		From the analyst's couch: value of novelty Many companies are shifting their discovery portfolios towards novel targets in the hope of developing more first-in-class drugs. Is this the right strategy? 1 August 2002
		From the analyst's couch: trends in development cycles Although recent trends show an encouraging decrease in overall development and approval times, the situation varies widely with therapeutic class. 1 May 2002
		From the analyst's couch: obesity market overview The market for therapies that target obesity is expected to triple by 2010 and the potential size of the market is stimulating intense preclinical research efforts. 1 April 2002
		Technology feature: Proteomics technology: character references What technologies are available to help us decipher the proteome, the task that, for many, remains the next big challenge? 25 October 2001
		Technology feature: Microarray technology: an array of opportunities How are manufacturers dealing with the explosion in microarray data? 25 April 2002
		From the analyst's couch: trends in development cycles Although recent trends show an encouraging decrease in overall development and approval times, the situation varies widely with therapeutic class. 1 May 2002
		From the analyst's couch: obesity market overview The market for therapies that target obesity is expected to triple by 2010 and the potential size of the market is stimulating intense preclinical research efforts. 1 April 2002
		From the analyst's couch: antiviral market overview In a field dominated by a few big pharmaceutical companies, new antiviral treatments are being focused on those who have already developed resistance to existing treatments. 1 January 2002